Vanguard Global Advisers
MRKR icon

Vanguard Global Advisers’s Marker Therapeutics MRKR Stock Holding History

Vanguard Global Advisers’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.69K Hold
2,512
– – ﹤0.01% 3577
2026
Q1 		$3.27K Buy
+2,512
New +$3.99K ﹤0.01% 3589

Other funds holding MRKR

BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Global Advisers's MRKR Position: Q2 2026 in Review

Vanguard Global Advisers held its Marker Therapeutics (MRKR) position steady in Q2 2026 at 2,512 shares worth $3.69K. The position accounts for ﹤0.01% of the portfolio, ranked #3577.

Vanguard Global Advisers first reported a position in MRKR in Q1 2026 and has held it in 2 quarters since. 34 funds tracked by Wall St. Rank hold MRKR as of Q2 2026.

  • Vanguard Global Advisers held 2,512 shares of Marker Therapeutics worth $3.69K as of Q2 2026.
  • Vanguard Global Advisers left its Marker Therapeutics share count unchanged in Q2 2026.
  • Marker Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3577 holding.
  • Vanguard Global Advisers first reported a position in Marker Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 34 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.